Review Article

Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis

Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, and Guiming Zhang

Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China

Correspondence should be addressed to Guiming Zhang; zhangguiming9@126.com

Received 18 March 2019; Accepted 10 August 2019; Published 3 September 2019

Academic Editor: Eric A. Singer

Copyright © 2019 Wen Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was performed to identify the prognostic impact of lymphovascular invasion (LVI) in patients with upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). A systematic search in PubMed, Embase, and the Cochrane Library was performed to identify relevant studies. The outcomes of interest, including progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were extracted, and the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used for effect size estimation. Subgroup, metaregression, and sensitivity analyses were performed to explore potential origins of heterogeneity. Publication bias was estimated by Egger’s linear regression and funnel plot. Our meta-analysis included a total of 27 studies involving 17,453 patients. The pooled HRs were statistically significant for PFS (HR = 1.73, 95% CI = 1.41–2.11), CSS (HR = 1.87, 95% CI = 1.54–2.27), and OS (HR = 1.56, 95% CI = 1.29–1.87), with high heterogeneity (I^2 = 77.8%, 70.3%, and 59.2%, respectively). Four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3–T4). The fixed effects model (I^2 = 33.9%) showed that the pooled HR was 1.64 (95% CI = 1.35–1.99) for CSS. Egger’s plots showed no significant publication bias (PFS: P = 0.443, CSS: P = 0.096, and OS: P = 0.894). Our meta-analysis demonstrated that LVI is a poor prognostic factor for UTUC and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality.

1. Introduction

Upper urinary tract urothelial carcinoma (UTUC) accounts for 10% of renal tumors and 5% of all urothelial malignancies [1, 2]. Radical nephroureterectomy (RNU) with the removal of the bladder cuff is the standard treatment of UTUC, including high-risk noninvasive and invasive UTUC [3, 4]. The incidence of invasive UTUC (approximately 60%) is much higher than that of bladder cancer. The prognosis of UTUC is poor worldwide, with a recurrence rate ranging from 30% to 75% [2, 5]. Therefore, an exploration of the potential prognostic factors in UTUC is important for risk classification. Many studies have indicated that older age, a history of bladder cancer, a higher tumor stage, a higher tumor grade, lymph node metastasis, multifocality, and hydronephrosis are predictors of disease recurrence or survival [1, 5, 6].

Lymphovascular invasion (LVI) is defined as the invasion of tumor cells into an endothelium-lined space of vascular or lymphatic vessels without underlying muscular walls [7]. The process of LVI is a crucial phase in the systemic dissemination of cancer cells [8]. In cancers of the liver, testis, and penis [9], LVI is included in the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging criteria for higher-risk patients, indicating that LVI might have a similar significance in the TNM classification. Many studies have estimated the prognostic influence of LVI in patients with UTUC, but the results remain controversial [10–36]. The European Association of Urology Guidelines indicate that LVI is an independent prognostic predictor of UTUC based on two retrospective studies [1]. One recent meta-analysis analyzed the prognostic value of LVI in UTUC but showed high heterogeneity [37]. Considering the new articles published in the past 5 years, we aimed to develop more
stringent inclusion and exclusion criteria with which to further validate the prognostic impact of LVI on UTUC and explore the potential factors causing heterogeneity.

2. Methods

2.1. Literature Search. We searched several electronic databases (PubMed, Embase, Web of Science, and the Cochrane Library) for relevant studies up to 31 December 2018. The following search terms were used to identify studies focusing on the prognostic value of LVI in UTUC: (1) “upper urinary tract” and “carcinoma” or “cancer” and “lymphovascular invasion”; (2) “upper urinary tract” and “carcinoma” or “cancer” and “survival” or “Cox” or “multivariable.”

2.2. Study Selection. We defined the inclusion and exclusion criteria before searching for articles. Studies were included if they met the following criteria: (1) the study evaluated LVI as a prognostic factor in patients with UTUC after RNU; (2) the study reported adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of progression-free survival (PFS), cancer-specific survival (CSS), or overall survival (OS) in a multivariate analysis with Cox proportional hazard regression; and (3) the study was published in English. The exclusion criteria were as follows: (1) the study did not provide sufficient data to acquire the HR and its standard error, (2) the article described a review or study on cell lines or animal models, (3) the number of cases was <100, (4) surgical treatment was not limited to RNU, and (5) neoadjuvant chemotherapy was applied to the participants. When more than one article was based on the same study population, we included the most complete or the most recent study.

2.3. Endpoints and Data Extraction. The endpoints of our study were PFS, CSS, and OS. Disease recurrence was defined as local failure or distant metastasis after surgery. CSS included only patients who died of UTUC, and OS included all causes of deaths. The extracted items were as follows: first author, publication year, region, recruitment period, number of cases, definition of LVI, LVI percentage, inclusion and exclusion criteria, definition of recurrence, and adjusted covariates (age, sex, operation, tumor location, lymph node status, history of bladder cancer, adjuvant chemotherapy, primary tumor stage, tumor grade, carcinoma in situ, margin status, hydronephrosis, multifocality, tumor architecture, body mass index, and adjusted HR with 95% CI of PFS, CSS, and OS). Two reviewers investigated relevant articles and extracted data, respectively. Disagreements between the two reviewers regarding data abstraction were resolved through discussion.

2.4. Statistical Analysis. The effect measures for the outcomes of PFS, CSS, and OS were the HRs and 95% CIs in the multivariable analysis with Cox proportional hazard regression, which were extracted from all included studies. LVI was considered an independent predictor if the pooled 95% CI did not overlap with 1 and \( P < 0.05 \). The \( I^2 \) statistic (total percentage of variation resulting from heterogeneity) was calculated to quantify the degree of heterogeneity. A fixed effects model was adopted to pool the HRs if \( I^2 \) was \( \leq 50\% \); otherwise, a random effects model was selected. We performed a subgroup analysis and a meta-regression analysis to explore potential heterogeneity. Next, a Galbraith plot was designed and a leave-one-out analysis was performed to search for studies causing heterogeneity and examine the weight of their influence on the pooled HR [38]. An influence analysis, in which one study was omitted and then the remaining studies were recalculated, was conducted to confirm the stability of the results. Publication bias was estimated by Egger’s linear regression and funnel plot. All reported \( P \) values were two-sided, and the statistical significance was set at \( P \leq 0.05 \). Statistical analysis was performed using Stata version 15.0 (Stata Corp., College Station, TX).

3. Results

3.1. Study Selection. The process of identifying relevant studies is illustrated in Figure 1. In total, 2985 articles were obtained from PubMed, Embase, and the Cochrane Library. After excluding 852 duplicate articles, we read 2133 titles and abstracts for further screening. Based on the information obtained from 291 original articles, 56 studies were excluded due to the presence of identical cohorts. Finally, 27 articles were included in this study to explore the prognostic value of LVI in UTUC [10–36], among which 4 articles analyzed LVI as a survival predictor in patients with advanced tumor stages (T3–T4) [10, 13, 16, 26].

3.2. Study Characteristics. Tables 1 and 2 summarize the characteristics of the 27 eligible studies. These 27 retrospective studies involved a total of 17,453 patients, with a wide recruitment period from 1987 to 2016. The number of male and female participants was 10,418 and 5320, respectively. Among the 27 studies, 9 assessed patients from Japan, 7 from China, 5 from Korea, 4 from Europe, and 2 from multiple countries. In total, 4217 patients with positive LVI were enrolled in our study, and the overall proportion of LVI was 24.2%. Studies including fewer than 100 patients were removed to limit heterogeneity; thus, the sample size of the enrolled studies ranged from 109 to 2492. Bladder recurrence was not considered a disease recurrence except in one study [18]. Twenty-two studies were adjusted for more than four covariates, and all studies adjusted for the effect of tumor stage and/or grade in the multivariable analysis.

3.3. Prognostic Value of LVI in UTUC. When \( I^2 > 50\% \), we used a random effects model to pool the HRs. The pooled HR was statistically significant for PFS (HR = 1.73, 95% CI = 1.41–2.11), CSS (HR = 1.87, 95%CI = 1.54–2.27), and OS (HR = 1.56, 95%CI = 1.29–1.87), with high heterogeneity (\( I^2 = 77.8\%, 70.3\%, \) and 59.2%, respectively) (shown in Figures 2(a)–2(c)). Four studies explored the prognostic influence of LVI in patients with advanced tumor stages (T3–T4). Through the fixed effects model (\( I^2 = 33.9\% \)), the pooled HR was 1.64 (95%CI = 1.35–1.99) for CSS (Figure 2(d)). We encompassed 6 studies that analyzed LVI as a survival predictor restricted to patients without lymph node metastasis and to those who have not undergone lymphadenectomy [16, 35, 39–42]. LVI was positively
associated with the higher risk of disease recurrence (PFS: HR = 2.17, 95%CI = 1.73–2.73) and cancer-specific mortality (CSS: HR = 2.13, 95%CI = 1.66–2.73), without heterogeneity (both $I^2 = 0\%$) (Figures 3(a) and 3(b)).

### 3.4. Subgroup Analysis and Sensitivity Analysis

To explore the source of potential heterogeneity, we classified the enrolled studies into those from Japan, Korea, China, and other regions (two from France, two from multiple regions, one from Germany, and one from Serbia). In PFS and CSS, the $I^2$ value decreased in groups of Japan, South Korea, and China (Table 3). The metaregression analysis showed that the performance of the studies in different regions might have been the origin of potential heterogeneity in PFS ($P = 0.055$) and CSS ($P = 0.011$). The Galbraith plot showed that one study revealed heterogeneity in OS (Figure 4); in the leave-one-out analysis, the heterogeneity decreased to 0.0% after excluding this study [22]. The sensitivity analysis showed that the pooled HRs of PFS, CSS, and OS were stable and that none of the studies could powerfully change the positive outcome. After omitting four studies in PFS and three in CSS by the leave-one-out analysis, a stable positive result (PFS: HR = 1.84, 95%CI = 1.65–2.06; CSS: HR = 2.23, 95%CI = 1.97–2.53) indicated the prognostic value of LVI in UTUC, with low heterogeneity (PFS: $I^2 = 4.4\%$; CSS: $I^2 = 2.2\%$).

### 3.5. Publication Bias

Egger’s plot showed no significant evidence of publication bias for any of the three outcomes (PFS: $P = 0.443$, CSS: $P = 0.096$, and OS: $P = 0.894$) (Figures 5(a)–5(c)). Likewise, the funnel plots showed no significant evidence of publication bias (data not shown).

### 4. Discussion

Because of the poor prognosis of UTUC, it is necessary to identify high-risk patients for individual therapy. LVI is included in the AJCC TNM staging criteria for cancers of the liver, testis, and penis [9]; in these staging criteria, LVI can upstage the cancer. Although LVI was shown to increase the prognostic risk of UTUC in many studies [29–33], it is not required for stage grouping in the AJCC cancer staging manual. The present study builds on a previous meta-analysis by including recently published studies that focus on the prognostic impact of LVI on UTUC [37]. Using more stringent inclusion and exclusion criteria, we aimed to

---

**Figure 1:** Flow chart for the identification of relevant articles.
| Study   | Author        | Country | Multicenter | No. of cases | Recruitment period | Exclude BC patients | Definition of LVI | No. of positive LVI (%) | Age (year) | Gender (male/female) | Definition of recurrence |
|---------|---------------|---------|-------------|--------------|-------------------|---------------------|-------------------|------------------------|------------|----------------------|--------------------------|
| 2018    | Ikeda et al.  | Japan   | Yes         | 441          | 1990-2015         | No                  | Yes               | 156 (37)              | 69.0 (62-75) | 319/122               | Excluding bladder recurrence |
| 2018    | Kohada et al. | Japan   | No          | 148          | 1999-2016         | No                  | No               | 55 (37)               | 71.0 (64-78) | 112/36                | Excluding bladder recurrence |
| 2018    | Abe et al.    | Japan   | Yes         | 214          | 2000-2015         | Yes                 | No               | 96 (45)               | 70.5 (35-93) | 151/63                | Excluding bladder recurrence |
| 2018    | Kim et al.    | Korea   | Yes         | 1521         | 2000-2012         | Yes                 | No               | 332 (22)              | 65.0 (57-72) | 1127/394              | Excluding bladder recurrence |
| 2018    | Tan et al.    | China   | No          | 710          | 2013-2016         | No                  | No               | 99 (15)               | 65.8       | 380/288               | Excluding bladder recurrence |
| 2018    | Kim et al.    | Korea   | Yes         | 1276         | 2000-2012         | Yes                 | No               | 258 (20)              | 65.7       | 941/335               | Excluding bladder recurrence |
| 2017    | Huang et al.  | China   | No          | 481          | 2003-2013         | Yes                 | No               | 76 (16)               | 65.8 (30-89) | 311/170               | Excluding bladder recurrence |
| 2017    | Nakagawa et al.| Japan   | Yes         | 109          | 1996-2013         | Yes                 | No               | 78 (72)               | 71.0 (64-77) | 67/42                 | Excluding bladder recurrence |
| 2017    | Cho et al.    | Korea   | Yes         | 1049         | 2004-2015         | Yes                 | No               | 202 (19)              | 68.5       | 759/290               | Including bladder recurrence |
| 2016    | Tai et al.    | China   | No          | 503          | 1996-2009         | Yes                 | No               | 87 (18)               | 68.7 (59-75) | 249/234               | Excluding bladder recurrence |
| 2016    | Shibing et al.| China   | Yes         | 795          | 2002-2012         | Yes                 | Yes              | 84 (11)               | NA         | 462/333               | Excluding bladder recurrence |
| 2016    | Song et al.   | China   | No          | 140          | 2005-2011         | Yes                 | No               | 6 (4)                 | NA         | 86/54                 | Excluding bladder recurrence |
| 2016    | Kobayashi et al.| Japan  | Yes         | 839          | 1990-2011         | Yes                 | Yes              | 326 (39)              | 70.4 (63-78) | 610/229               | Excluding bladder recurrence |
| 2016    | Waseda et al. | Japan   | Yes         | 1068         | 1995-2013         | Yes                 | No               | 446 (42)              | 70.0 (62-76) | 758/310               | Excluding bladder recurrence |
| 2016    | Mbeutcha et al.| International | Yes | 716          | 1990-2008         | No                 | No               | 149 (21)              | 70.0 (63-76) | 400/316               | NA |
| 2016    | Kim et al.    | Korea   | No          | 371          | 1992-2012         | Yes                 | Yes              | 71 (19)               | 64.7       | 287/84                | NA |
| 2016    | Matsumoto et al.| Japan    | No | 144          | 1995-2010         | No                 | No               | 93 (65)               | 71.0 (14-98) | 104/40                | NA |
| 2015    | Hara et al.   | Japan   | Yes         | 1172         | 2005-2011         | No                 | Yes              | 423 (36)              | 71.0 (21-97) | 806/366               | Excluding bladder recurrence |
| 2015    | Tanaka et al. | Japan   | Yes         | 394          | 1995-2011         | Yes                 | Yes              | 170 (43.1)            | 70.0       | 289/105               | Excluding bladder recurrence |
| 2015    | Lee et al.    | China   | No          | 250          | 2004-2010         | Yes                 | Yes              | 60 (24)               | NA         | 108/142               | Excluding bladder recurrence |
Table 1: Continued.

| Study  | Author          | Country | Multicenter | No. of cases | Recruitment period | Exclude BC patients | Definition of LVI | No. of positive LVI (%) | Age (year) | Gender (male/female) | Definition of recurrence |
|--------|-----------------|---------|-------------|--------------|-------------------|---------------------|-------------------|------------------------|-------------|----------------------|--------------------------|
| 2015   | Kang et al.     | Korea   | Yes         | 440          | 2001-2013         | Yes                 | No                | 76 (17)                | NA          | 305/135               | Excluding bladder recurrence |
| 2015   | Milojevic et al.| Serbia  | No          | 238          | 1999-2013         | Yes                 | No                | 154 (65)               | 66.5        | 132/106               | Excluding bladder recurrence |
| 2014   | Aziz et al.     | Germany | No          | 256          | 1990-2012         | Yes                 | Yes               | 52 (20)                | 68.6        | 169/96                | Excluding bladder recurrence |
| 2013   | Liu et al.      | China   | Yes         | 421          | 1999-2010        | Yes                 | Yes               | 101 (24)               | NA          | 285/136               | Excluding bladder recurrence |
| 2013   | Hurel et al.    | France  | Yes         | 551          | 1995-2010        | Yes                 | Yes               | 163 (30)               | 69.4        | 365/188               | Excluding bladder recurrence |
| 2013   | Ouzzane et al.  | France  | Yes         | 714          | 1995-2010        | Yes                 | No                | 157 (22)               | 70.0        | 484/228               | Excluding bladder recurrence |
| 2012   | Chromecki et al.| International | Yes | 2492 | 1987-2007 | Yes         | Yes               | 247 (10)              | 69.2        | 1681/811              | Excluding bladder recurrence |

NA: not available; BC: bladder cancer; LVI: lymphovascular invasion.
Table 2: Outcomes of studies included in meta-analysis.

| Year | Author          | PFS HR (95% CI)       | CSS HR (95% CI)     | OS HR (95% CI)     | No. of covariates | Adjusted variables (part)                                                                 |
|------|-----------------|-----------------------|---------------------|-------------------|------------------|--------------------------------------------------------------------------------------------|
| 2018 | Ikeda et al.    | 2.51 (1.552-4.07)     | 3.5 (1.954-6.259)   | NA                | 11               | Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture |
| 2018 | Kohada et al.   | 2.65 (1.52-4.67)      | 2.62 (1.06-6.96)    | NA                | 5                | pT, tumor grade, hydronephrosis                                                               |
| 2018 | Abe et al.      | 1.162 (0.647-2.133)   | 2.11 (0.988-4.839)  | 1.326 (0.697-2.52) | 3                | Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture |
| 2018 | Kim et al.      | 1.76 (1.4-2.21)       | 1.9 (1.49-2.44)     | 1.85 (1.48-2.31)  | 14               | Age, gender, tumor location, pN, adjuvant therapy, tumor grade, tumor architecture, multifocality |
| 2018 | Tan et al.      | 1.02 (0.73-1.43)      | 1.16 (0.79-1.7)     | 1.16 (0.82-1.65)  | 14               | Tumor grade, tumor architecture, margin status, pN                                           |
| 2018 | Kim et al.      | 1.859 (1.464-2.36)    | 1.829 (1.43-2.338)  | 1.776 (1.36-2.32) | 8                | Age, pN, pT, tumor grade, multifocality                                                      |
| 2017 | Huang et al.    | NA                    | 1.72 (1.14-2.59)    | 1.51 (1.04-2.2)   | 6                | Age, adjuvant therapy, tumor grade, hydronephrosis                                           |
| 2017 | Nakagawa et al. | 2.02 (0.85-5.61)      | 3.02 (0.76-20.43)   | NA                | 5                | Age, gender, operation, tumor location, pN, history of BC, pT, CIS, hydronephrosis, multifocality, BMI |
| 2017 | Cho et al.      | 1.69 (1.37-2.09)      | 2.78 (1.88-4.1)     | 1.98 (1.42-2.77)  | 19               | Tumor location, pT, tumor grade, tumor architecture                                           |
| 2016 | Tai et al.      | 1.05 (0.56-1.95)      | NA                  | NA                | 3                | Age, operation, tumor location, pN, pT, tumor grade, tumor architecture                       |
| 2016 | Shibing et al.  | 0.802 (0.6-1.072)     | 0.909 (0.68-1.215)  | 0.913 (0.695-1.2) | 10               | Age, gender, tumor location, history of BC, pT, tumor grade, hydronephrosis                  |
| 2016 | Song et al.     | 3.165 (0.487-20.565)  | 4.898 (0.563-42.626)| NA                | 15               | Age, gender, pN, adjuvant therapy, pT, tumor grade                                           |
| 2016 | Kobayashi et al.| 2.02 (1.46-2.8)       | 2.28 (1.55-3.36)    | NA                | 6                | Age, tumor location, pN, pT, tumor grade                                                    |
| 2016 | Waseda et al.   | 2.7 (1.97-3.69)       | 2.83 (1.95-4.1)     | NA                | 5                | Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture |
| 2016 | Mbeutcha et al. | NA                    | 1.23 (0.83-1.81)    | 1.35 (0.98-1.87)  | 12               | Tumor location, history of BC, tumor grade                                                  |
| 2016 | Matsumoto et al.| 1.88 (0.73-5.03)      | 1.32 (0.46-3.82)    | 1.07 (0.44-2.61)  | 6                | Age, adjuvant therapy, pT, tumor grade                                                      |
| 2016 | Kim et al.      | NA                    | 1.82 (0.99-3.32)    | NA                | 3                | pT, tumor grade                                                                              |
| 2015 | Tanaka et al.   | NA                    | NA                  | 1.67 (1.01-2.74)  | 4                | Tumor location, history of BC, tumor grade                                                   |
| 2015 | Hara et al.     | 3.19 (2.09-4.87)      | NA                  | NA                | 16               | Age, adjuvant therapy, pT, tumor grade                                                      |
| 2015 | Lee et al.      | 1.71 (1-2.93)         | 1.38 (0.69-2.75)    | NA                | 4                | Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, margin status |

Disease Markers
| Year | Author         | PFS HR (95% CI) | CSS HR (95% CI) | OS HR (95% CI) | No. of covariates | Adjusted variables (part)                                                                 |
|------|----------------|-----------------|-----------------|----------------|-------------------|-------------------------------------------------------------------------------------------|
| 2015 | Kang et al.    | NA              | 3.097 (1.81-5.297) | 2.4 (1.469-3.921) | 9                 | Age, adjuvant therapy, pT, tumor grade, margin status, multifocality, adjuvant therapy, BMI |
| 2015 | Milojevic et al.| 0.58 (0.32-1.07) | NA              | NA             | 5                 | pN, history of BC, adjuvant therapy, pT, tumor grade                                      |
| 2014 | Aziz et al.    | 2.7 (1.59-4.57)  | 2.5 (1.45-4.3)   | 1.91 (1.22-2.98) | 10                | Age, tumor location, pN, pT, tumor grade, tumor architecture, multifocality               |
| 2013 | Liu et al.     | NA              | 1.16 (0.818-1.645) | NA             | 13                | Age, gender, operation, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status, multifocality |
| 2013 | Hurel et al.   | 2.14 (1.38-3.3)  | 1.73 (1.01-2.95) | NA             | 8                 | Age, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status                 |
| 2013 | Ouazzane et al.| NA              | NA              | 1.57 (1.03-2.4)  | 6                 | Age, tumor location, pN, pT, tumor grade, margin status                                   |
| 2012 | Chromecki et al.| 1.31 (1.1-1.57)  | 1.41 (1.16-1.72) | NA             | 10                | Age, gender, tumor location, pN, adjuvant therapy, pT, tumor grade, tumor architecture, multifocality |

NA: not available; BC: bladder cancer; PFS: progression-free survival; CSS: cancer-specific survival; OS: overall survival; HR: hazard ratio; CIS: carcinoma in situ; pT: pathological tumor stage; pN: pathological lymph node.
### Study ID

| Study ID       | HR (95% CI)          | % weight |
|----------------|----------------------|----------|
| Ikeda M (2018) | 2.51 (1.55, 4.07)    | 5.74     |
| Kohada Y (2018)| 2.65 (1.52, 4.67)    | 5.14     |
| Takashige A (2018) | 1.16 (0.65, 2.13) | 4.89     |
| Kim TH (2018)  | 1.76 (1.40, 2.21)    | 7.68     |
| Nakagawa T (2017) | 2.02 (0.85, 5.61) | 2.99     |
| Cho YH (2017)  | 1.69 (1.37, 2.09)    | 7.79     |
| Tai YS (2016)  | 1.05 (0.56, 1.95)    | 4.71     |
| Shibing Y (2016)| 0.80 (0.60, 1.07)  | 7.24     |
| Song X (2016)  | 3.00 (0.49, 20.56)   | 1.03     |
| Kobayashi H (2016)| 2.02 (1.46, 2.80) | 6.98     |
| Chromecki TF (2012)| 3.10 (1.81, 5.30)| 6.63     |
| Hara T (2015)  | 3.91 (2.09, 3.48)    | 6.20     |
| Overall (I² = 77.8%, P = 0.000) | 1.73 (1.41, 2.11) | 100.00   |

Note: weights are from random effects analysis

---

### Study ID

| Study ID       | HR (95% CI)          | % weight |
|----------------|----------------------|----------|
| Ikeda M (2018) | 3.50 (1.95, 6.26)    | 4.99     |
| Kohada Y (2018)| 2.62 (1.06, 6.96)    | 2.89     |
| Takashige A (2018) | 2.11 (0.99, 4.84) | 3.60     |
| Kim TH (2018)  | 1.90 (1.49, 2.44)    | 7.90     |
| Huang J (2017) | 1.72 (1.14, 2.59)    | 6.45     |
| Nakagawa T (2017) | 3.02 (0.76, 20.43)| 1.21     |
| Cho YH (2017)  | 2.78 (1.88, 4.10)    | 6.63     |
| Shibing Y (2016)| 0.91 (0.68, 1.22)   | 7.53     |
| Song X (2016)  | 4.90 (0.56, 42.63)   | 0.74     |
| Kobayashi H (2016)| 2.28 (1.55, 3.36) | 6.66     |
| Waseda Y (2016)| 2.83 (1.95, 4.10)    | 6.80     |
| Mbeutcha A (2016)| 1.23 (0.83, 1.81)| 6.63     |
| Lee HY (2015)  | 1.38 (0.69, 2.75)    | 4.21     |
| Kang HW (2015) | 3.10 (1.81, 5.30)    | 5.35     |
| Atiqullah A (2014)| 2.50 (1.45, 4.30)| 5.30     |
| Liu J Y (2013) | 1.16 (0.82, 1.64)    | 7.00     |
| Hurel S (2013) | 1.73 (1.01, 2.95)    | 5.36     |
| Chromecki TF (2012)| 1.41 (1.16, 1.72) | 8.29     |
| Matsumoto H (2016)| 1.32 (0.46, 3.82) | 2.45     |
| Overall (I² = 70.3%, P = 0.000) | 1.87 (1.54, 2.27) | 100.00   |

Note: weights are from random effects analysis

---

Figure 2: Continued.
further validate the prognostic risk of LVI and explore the potential factors causing heterogeneity.

In this meta-analysis, we identified 18 studies evaluating PFS, 19 evaluating CSS, 11 evaluating OS, 4 evaluating the CSS of patients with advanced tumor stages, and 6 evaluating the PFS and CSS in node-negative patients. Given the rarity of UTUC, it is notable that the present meta-analysis has a higher sample size than that of a previously published meta-analysis [37] and has the largest amount of data. Compared with patients with UTUC and no LVI, patients with concurrent UTUC and LVI had a 1.73-fold higher risk of developing disease recurrence (HR = 1.73, 95%CI = 1.41–2.11) and a 1.87-fold higher risk of cancer-specific death (HR = 1.87, 95%CI = 1.54–2.27), suggesting that LVI is an independent prognostic predictor in patients with UTUC. These results are congruent with those of a previous meta-

| Study ID            | HR (95% CI)       | % weight |
|---------------------|-------------------|----------|
| Takashige A (2018)  | 1.33 (0.70, 2.52) | 5.60     |
| Kim T H (2018)      | 1.85 (1.48, 2.31) | 13.57    |
| Huang J (2017)      | 1.51 (1.04, 2.20) | 10.01    |
| Cho YH (2017)       | 1.98 (1.42, 2.77) | 10.91    |
| Shibing Y (2016)    | 0.91 (0.69, 1.20) | 12.36    |
| Mbeutcha A (2016)   | 1.35 (0.98, 1.87) | 11.17    |
| Kang HW (2015)      | 2.40 (1.47, 3.92) | 7.75     |
| Atiqullah A (2014)  | 1.91 (1.22, 2.98) | 8.55     |
| Matsumoto H (2016)  | 1.07 (0.44, 2.61) | 3.47     |
| Tanaka N (2015)     | 1.67 (1.01, 2.74) | 7.61     |
| Ouzzane A (2013)    | 1.57 (1.03, 2.40) | 9.00     |
| Overall (I² = 59.2%, P = 0.006) | 1.56 (1.29, 1.87) | 100.00   |

Note: weights are from random effects analysis

| Study ID            | HR (95% CI)       | % weight |
|---------------------|-------------------|----------|
| Nakagawa, T. (2017) | 3.02 (0.76, 20.43)| 1.40     |
| Tan P (2018)        | 1.16 (0.79, 1.70) | 25.74    |
| Kim SH (2018)       | 1.83 (1.43, 2.34) | 62.54    |
| Kim HS (2016)       | 1.82 (0.99, 3.32) | 10.32    |
| Overall (I² = 33.9%, P = 0.209) | 1.64 (1.35, 1.99) | 100.00   |

Note: weights are from fixed effects analysis

**Figure 2:** Forest plots of hazard ratios (HRs) for the association between lymphovascular invasion and upper urinary tract urothelial carcinoma. (a) Progression-free survival (PFS). (b) Cancer-specific survival (CSS). (c) Overall survival (OS). (d) Lymphovascular invasion and CSS in patients with advanced tumor stages (T3–T4).
analysis that reported a positive association of LVI with oncologic outcomes, with a pooled HR of 1.91 and 1.72 for PFS and CSS, respectively [37]. Ku et al. did not prove that LVI was an independent factor in UTUC based on two studies (HR = 4.05, 95% CI = −0.44 to 8.53) [37]. However, LVI was evaluated as a strong predictor of poor OS in patients with UTUC (HR = 1.56, 95% CI = 1.29–1.87) through pooling of 11 studies. Only four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3–T4). Through our fixed effects model ($I^2 = 33.9\%$), the pooled HR showed that LVI could increase the risk of cancer-specific death (HR = 1.64, 95%
Unfortunately, most articles did not investigate the relationship between LVI and different stages of UTUC; thus, adding LVI as a predictor to TNM staging requires studies that focus on stratification of the tumor stage. Novara et al. have investigated the interaction between LVI and lymph node stage [40]. They found that LVI was associated with PFS and CSS in patients with negative lymph nodes, not in lymph node-positive patients. In our study, we revealed that the presence of LVI increased the risk of both disease recurrence and cancer-specific mortality in patients with pN0 and pNx disease (HR = 2.17 and 2.13, respectively). There was no sufficient data for us to explore the effect of LVI on node-positive patients. LVI was an essential and important step in the systemic dissemination of cancer cells [40]. Although lymph node metastasis at the time of RNU could be a reliable prognostic predictor of recurrence, no standard guideline for the appropriate area of lymphadenectomy during RNU has been established [35]. Therefore, LVI could identify patients without lymph node involvement or undergoing lymph node resection who are at an increased risk of cancer recurrence and mortality. Our study represents a more comprehensive analysis of the effect of LVI on UTUC and prompts both urologists and oncologists to select patients at a higher risk of recurrence or death because such patients may be candidates for further therapy (adjuvant chemotherapy) or more intense follow-up. On this basis,

| Region | No. of studies | Weight (%) | OR (95% CI) | \( I^2 \) | \( P \) for heterogeneity | \( P^* \) for interaction |
|--------|----------------|------------|-------------|-------|------------------------|-------------------------|
| PFS    | 18             | 100.00     | 1.73 (1.41-2.11) | 77.8% | <0.001                 | 0.055                   |
| Japan  | 8              | 41.91      | 2.32 (1.90-2.83) | 26.3% | 0.219                  |                         |
| Korea  | 2              | 15.47      | 1.72 (1.47-2.01) | 0.0%  | 0.798                  |                         |
| China  | 4              | 18.30      | 1.15 (0.72-1.84) | 59.3% | 0.061                  |                         |
| Othersa| 4              | 24.32      | 1.47 (0.89-2.43) | 83.6% | <0.001                 |                         |
| CSS    | 19             | 100.00     | 1.87 (1.54-2.27) | 70.3% | <0.001                 | 0.111                   |
| Japan  | 7              | 28.60      | 2.57 (2.06-3.20) | 0.0%  | 0.743                  |                         |
| Korea  | 3              | 19.89      | 2.40 (1.74-3.29) | 53.3% | 0.117                  |                         |
| China  | 5              | 25.94      | 1.25 (0.92-1.69) | 51.2% | 0.085                  |                         |
| Othersa| 4              | 25.57      | 1.54 (1.20-1.97) | 39.9% | 0.172                  |                         |
| OS     | 11             | 100.00     | 1.56 (1.29-1.87) | 59.2% | <0.001                 | 0.636                   |
| Japan  | 3              | 16.68      | 1.44 (1.01-2.07) | 0.0%  | 0.661                  |                         |
| Korea  | 3              | 32.24      | 1.95 (1.64-2.31) | 0.0%  | 0.635                  |                         |
| China  | 2              | 22.37      | 1.15 (0.71-1.89) | 77.9% | 0.033                  |                         |
| Othersa| 3              | 28.72      | 1.53 (1.23-1.92) | 0.0%  | 0.463                  |                         |

*P-values for meta-regression. *Two studies from France, two from multiple countries, one from German, and one from Serbia. PFS: progression-free survival; CSS: cancer-specific survival; OS: overall survival.

Figure 4: Galbraith plot showing the potential heterogeneity for overall survival. b: regression coefficient; SE: standard error.
Figure 5: Egger’s funnel plots for publication bias. (a) Progression-free survival (PFS). (b) Cancer-specific survival (CSS). (c) Overall survival (OS). SND: standard normal deviate; CI: confidence interval.
pathologists should routinely perform an exhaustive pathological assessment of UTUC specimens to identify LVI [43]. We developed more stringent exclusion criteria and conducted a subgroup analysis to decrease the clinical heterogeneity. Studies with fewer than 100 patients were excluded to rule out interference with the outcomes [43]. Studies that included neoadjuvant chemotherapy or conservative surgery, such as segmental ureterectomy with termino-terminal anastomosis, were omitted to maintain the analysis of only a single treatment (RNU) with adjuvant chemotherapy. The utility of neoadjuvant chemotherapy in patients with UTUC remains uncertain, and additional trials are thus needed; however, adjuvant chemotherapy can increase CSS and OS in patients with UTUC [44]. After the studies had been classified by region, the heterogeneity of PFS and CSS was significantly reduced except in China. For further analysis, we designed a Galbraith plot and performed a leave-one-out analysis and identified one study from China causing heterogeneity in all three outcomes [22]. This might have been due to the low percentage (11%) of LVI, which was diagnosed depending on the level of pathologists. Nonetheless, the pooled HRs of each group in the three outcomes were still positive, excluding the study from China; therefore, we considered that LVI was an independent prognostic predictor in UTUC despite the high heterogeneity. There was no heterogeneity between LVI and lymph node-negative patients, indicating the strongly predictive value of LVI on them.

The biological mechanisms of the positive association between LVI and poor UTUC outcomes are complex. LVI is defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls [7] and is an important step in tumor dissemination. Tumor cells enter the circulation through the lymphatic and blood vessels, forming micrometastases [45]. Additionally, LVI has been linked with lymph node involvement and is suggested to be a prerequisite for lymph node invasion [35, 40, 45]. Lymph node metastasis is included in the TNM classification. More importantly, the presence of LVI is associated with disease recurrence or mortality in patients with node-negative UTUC, but not in those with node-positive UTUC [40, 45]. Moreover, LVI significantly increases the risk of disease recurrence, cancer-specific mortality, and overall mortality after effective local treatment (RNU). Based on these above-described factors, LVI is considered to play an important role in the metastatic process and promote a poor prognosis [45].

To the best of our knowledge, this meta-analysis is the most comprehensive of its kind to identify the association between LVI and poor outcomes of UTUC. This meta-analysis has several strengths. First, we adopted the largest sample size (17,453 patients), although we used more stringent inclusion and exclusion criteria. This massive study population enhances the statistical power and ensures more accurate risk estimation. Second, this is the first analysis of the influence of LVI in patients with advanced tumor stages (T3–T4) and lymph node-negative UTUC through a meta-analysis with low heterogeneity. Third, no publication bias existed in our study. Our meta-analysis also had several limitations. First, all enrolled articles were retrospective studies; thus, many confounding factors could not be corrected because of a lack of patient information. For this reason, the outcomes of our meta-analysis might deviate from the actual situation in the clinical setting. Second, significant heterogeneity was found for PFS, CSS, and OS. However, we found the potential origin of heterogeneity and the article causing heterogeneity through subgroup, meta-regression, and leave-one-out analyses. After excluding the article from China, the I² of PFS, CSS, and OS decreased to 68%, 58%, and 0%, respectively. The heterogeneity mainly came from the geographical region (for PFS and CSS). Although a random-effects model was used and many statistical methods were implemented, the conclusions reached in our meta-analysis should be interpreted with caution.

5. Conclusions

In conclusion, the pooled results demonstrate that LVI is a significant prognostic factor for UTUC, especially for lymph node-negative patients, and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality. It can also denote a poor prognosis of UTUC with an advanced tumor stage (T3–T4). We advocate systematic assessment of LVI after RNU using pathological specimens. The results of this meta-analysis need to be further confirmed by adequately designed prospective studies before LVI is included in the AJCC TNM staging system of UTUC.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

This study was partly funded by the National Natural Science Foundation of China (Grant Nos. NSFC 81502195 and 81672512) and the Health Science Technology Development Project of Shandong Province (Grant No. 2016WS0258). We thank Angela Morben, DVM, ELS, from Liwen Bianji, Edanz Editing, China (http://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

References

[1] M. Roupêt, M. Babjuk, E. Compérat et al., “European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update,” European Urology, vol. 73, no. 1, pp. 111–122, 2018.
[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
[3] E. Xylinas, M. Rink, V. Margulis et al., “Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence,” European Urology, vol. 61, no. 5, pp. 1069–1070, 2012.
[4] V. Margulis, S. F. Shariat, S. F. Matin et al., “Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration,” Cancer, vol. 115, no. 6, pp. 1224–1233, 2009.
Disease Markers

[5] X. K. Zhang, Z. L. Zhang, P. Yang et al., “Tumor necrosis predicts poor clinical outcomes in patients with node-negative upper urinary tract urothelial carcinoma,” *Japanese Journal of Clinical Oncology*, vol. 45, no. 11, pp. 1069–1075, 2015.

[6] S. Morizane, H. Iwamoto, T. Masago et al., “Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma,” *International Urology and Nephrology*, vol. 45, no. 1, pp. 99–106, 2013.

[7] H. J. Kahn and A. Marks, “A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors,” *Laboratory Investigation*, vol. 82, no. 9, pp. 1255–1257, 2002.

[8] S. S. Sundar and T. S. Ganesan, “Role of lymphangiogenesis in cancer,” *Journal of Clinical Oncology*, vol. 25, no. 27, pp. 4298–4307, 2007.

[9] M. B. Amin, F. L. Greene, S. B. Edge et al., “The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging,” *CA: A Cancer Journal for Clinicians*, vol. 67, no. 2, pp. 93–99, 2017.

[10] P. Tan, J. Chen, N. Xie et al., “Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma?,” *Cancer Medicine*, vol. 7, no. 10, pp. 5096–5106, 2018.

[11] Y. Kohada, T. Hayashi, K. Goto et al., “Preoperative risk classification using neutrophil-lymphocyte ratio and hydrenephrosis for upper tract urothelial carcinoma,” *Japanese Journal of Clinical Oncology*, vol. 48, no. 9, pp. 841–850, 2018.

[12] T. H. Kim, B. Hong, H. K. Seo et al., “The comparison of oncologic outcomes between open and laparoscopic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: a Korean multicenter collaborative study,” *Cancer Research and Treatment*, vol. 51, no. 1, pp. 240–251, 2019.

[13] S. H. Kim, M. K. Song, J. K. Kim et al., “Laparoscopy versus open nephroureterectomy in prognostic outcome of patients with advanced upper tract urothelial cancer: a retrospective, multicenter, propensity-score matching analysis,” *Cancer Research and Treatment*, vol. 51, no. 3, pp. 963–972, 2019.

[14] M. Ikeda, K. Matsumoto, T. Hirayama et al., “Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study,” *Clinical Genitourinary Cancer*, vol. 16, no. 3, pp. e669–e675, 2018.

[15] T. Abe, T. Kondo, T. Harabayashi et al., “Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection,” *Japanese Journal of Clinical Oncology*, vol. 48, no. 11, pp. 1001–1011, 2018.

[16] T. Nakagawa, Y. Komemushi, T. Kawai et al., “Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study,” *World Journal of Urology*, vol. 35, no. 10, pp. 1569–1575, 2017.

[17] J. Huang, Y. Yuan, Y. Wang et al., “Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma,” *Oncotarget*, vol. 8, no. 22, pp. 36761–36771, 2017.

[18] Y. H. Cho, J. E. Hwang, H. S. Chung et al., “The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma,” *International Urology and Nephrology*, vol. 49, no. 8, pp. 1383–1390, 2017.

[19] Y. Waseda, K. Saito, J. Ishioka et al., “Ureteral involvement is associated with poor prognosis in upper urinary tract urothelial carcinoma patients treated by nephroureterectomy: a multicenter database study,” *European Urology Focus*, vol. 2, no. 3, pp. 296–302, 2016.

[20] Y. S. Tai, C. H. Chen, C. Y. Huang, H. C. Tai, S. M. Wang, and Y. S. Pu, “The effect of tumor location on oncologic outcomes in patients with upper urinary tract urothelial carcinoma stratified by pathologic stage,” *Urologic oncology*, vol. 34, no. 1, pp. 4.e19–4.e25, 2016.

[21] X. Song, G. M. Zhang, X. C. Ma et al., “Comparison of preoperative neutrophil-lymphocyte, lymphocyte-monocyte, and platelet-lymphocyte ratios in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy,” *OncoTargets and Therapy*, vol. 9, pp. 1399–1407, 2016.

[22] Y. Shibing, L. Liangren, W. Qiang et al., “Impact of tumour size on prognosis of upper urinary tract urothelial carcinoma after radical nephroureterectomy: a multi-institutional analysis of 795 cases,” *BJU International*, vol. 118, no. 6, pp. 902–910, 2016.

[23] A. Mbeutcha, I. Lucca, V. Margulis et al., “Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent,” *World Journal of Urology*, vol. 34, no. 8, pp. 1155–1161, 2016.

[24] H. Matsumoto, M. Munemori, K. Shimizu et al., “Risk stratification using Bmi-1 and Snail expression is a useful prognostic tool for patients with upper tract urothelial carcinoma,” *International Journal of Urology*, vol. 23, no. 12, pp. 1030–1037, 2016.

[25] H. Kobayashi, E. Kikuchi, N. Tanaka et al., “Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy,” *Japanese Journal of Clinical Oncology*, vol. 46, no. 6, pp. 554–559, 2016.

[26] H. S. Kim, J. H. Ku, C. W. Jeong, C. Kwak, and H. H. Kim, “Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma,” *World Journal of Urology*, vol. 34, no. 6, pp. 859–869, 2016.

[27] N. Tanaka, E. Kikuchi, K. Kanao et al., “Impact of combined use of blood-based inflammatory markers on patients with upper tract urothelial carcinoma following radical nephroureterectomy: proposal of a cumulative marker score as a novel predictive tool for prognosis,” *European Urology Focus*, vol. 1, no. 1, pp. 54–63, 2015.

[28] B. Milojovic, Z. Dzamic, B. Kajmakovic, O. Durutovic, U. Bumbasirevic, and S. Sipetic Grujicic, “Prognostic impact of preoperative anemia on urothelial and extraurothelial recurrence in patients with upper tract urothelial carcinoma,” *Clinical Genitourinary Cancer*, vol. 13, no. 5, pp. 485–491, 2015.

[29] H. Y. Lee, C. C. Li, C. N. Huang et al., “Prognostic significance of lymphovascular invasion in upper urinary tract urothelial carcinoma is influenced by tumor location,” *Annals of Surgical Oncology*, vol. 22, no. 4, pp. 1392–1400, 2015.

[30] H. W. Kang, H. D. Jung, Y. S. Ha et al., “Preoperative underweight patients with upper tract urothelial carcinoma survive less after radical nephroureterectomy,” *Journal of Korean Medical Science*, vol. 30, no. 10, pp. 1483–1489, 2015.
[31] T. Hara, H. Fujimoto, M. Sakura et al., "Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: subanalysis of the multi-institutional national database of the Japanese Urological Association," International Journal of Urology, vol. 22, no. 11, pp. 1013–1020, 2015.

[32] A. Aziz, M. Rink, G. Gakis et al., "Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy," Urologia Internationalis, vol. 93, no. 3, pp. 352–360, 2014.

[33] A. Ouzzane, P. Colin, T. P. Ghoneim et al., "The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy," World Journal of Urology, vol. 31, no. 6, pp. 1989–1997, 2013.

[34] J. Y. Liu, Y. H. Li, Z. L. Zhang et al., "Age-specific effect of gender on upper tract urothelial carcinoma outcomes," Medical Oncology, vol. 30, no. 3, p. 640, 2013.

[35] S. Hurel, M. Rouprêt, A. Ouzzane et al., "Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy," BJU International, vol. 111, no. 8, pp. 1199–1207, 2013.

[36] T. F. Chromecki, E. K. Cha, H. Fajkovic et al., "The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy," European Urology, vol. 61, no. 2, pp. 245–253, 2012.

[37] J. H. Ku, S. S. Byun, H. Jeong, C. Kwak, H. H. Kim, and S. E. Lee, "Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: a systematic review and meta-analysis," European Journal of Cancer, vol. 49, no. 12, pp. 2665–2680, 2013.

[38] B. C. Wallace, C. H. Schmid, J. Lau, and T. A. Trikalinos, "Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data," BMC Medical Research Methodology, vol. 9, no. 1, p. 80, 2009.

[39] D. S. Kim, Y. H. Lee, K. S. Cho, N. H. Cho, B. H. Chung, and S. I. Hong, "Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma," Urology, vol. 75, no. 2, pp. 328–332, 2010.

[40] G. Novara, K. Matsumoto, W. Kassouf et al., "Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study," European Urology, vol. 57, no. 6, pp. 1064–1071, 2010.

[41] K. Saito, S. Kawakami, Y. Fujii, M. Sakura, H. Masuda, and K. Kihara, "Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically," The Journal of Urology, vol. 178, no. 6, pp. 2291–2296, 2007.

[42] N. Tanaka, E. Kikuchi, K. Matsumoto et al., "Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma," BJU International, vol. 111, no. 6, pp. 857–864, 2013.

[43] F. Petrelli, M. I. Yasser Hussein, I. Vavassori, and S. Barni, "Prognostic factors of overall survival in upper urinary tract carcinoma: a systematic review and meta-analysis," Urology, vol. 100, pp. 9–15, 2017.

[44] J. J. Leow, W. Martin-Doyle, A. P. Fay, T. K. Choueiri, S. L. Chang, and J. Bellmunt, "A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma," European Urology, vol. 66, no. 3, pp. 529–541, 2014.

[45] E. Kikuchi, V. Margulis, P. I. Karakiewicz et al., "Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma," Journal of Clinical Oncology, vol. 27, no. 4, pp. 612–618, 2009.